Olanzapine versus haloperidol treatment in first-episode psychosis

American Journal of Psychiatry

Volumn 156, Issue 1, 1999, Pages 79-87

  Sanger, Todd M ^a   Lieberman, Jeffery A ^b   Tohen, Mauricio ^b   Grundy, Starr ^b   Beasley Jr , Charles ^b   Tollefson, Gary D ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RISK BENEFIT ANALYSIS; SCORING SYSTEM;

EID: 0032921705     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.1.79     Document Type: Article

References (55)

1. Torrey EF (ed) Surviving Schizophrenia: A Manual for Families, Consumers, and Providers. New York, HarperCollins, 1995, p 409
2. Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM: The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophr Bull 1992; 18:273-282
3. Ciompi L: The natural history of schizophrenia in the long term. Br J Psychiatry 1980; 136:412-420
4. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
5. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M: Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-1436
6. Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos MJ, Silver P: Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47:761-768
7. McGlashan TH: A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988; 14:515-542
8. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325-351
9. Lieberman JA, Kinon BJ, Loebel AD: Dopaminergic mechanisms of idiopathic and drug induced psychosis. Schizophr Bull 1990; 16:97-110
10. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M: Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14(March suppl):13S-21S
11. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-1188
12. Hoff AL, Riordan H, O'Donnell D, Stritzke P, Neale C, Boccio A, Anand AK, DeLisi LE: Anomalous lateral sulcus asymmetry and cognitive function in first-episode schizophrenia. Schizophr Bull 1992; 18:257-272; correction, 1994; 20:248
13. Hoff AL, Riordan H, O'Donnell D, Stritzke P, Neale C, Boccio A, Anand AK, DeLisi LE: Anomalous lateral sulcus asymmetry and cognitive function in first-episode schizophrenia. Schizophr Bull 1992; 18:257-272; correction, 1994; 20:248
14. Nopoulos P, Flashman L, Flaum M, Arndt S, Andreasen N: Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res 1994; 14:29-37
15. Sweeney JA, Haas GL, Keilp JG, Long M: Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year follow-up study. Psychiatry Res 1991; 38:63-76
16. Keefe RSE, Perkins D, Lieberman JA: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a meta-analysis and methodological review. Schizophr Bull 1998 (in press)
17. Wyatt RJ: Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 1995; 38:1-3
18. Lieberman JA: Understanding the mechanism of atypical antipsychotic drugs: a review of compounds in use and development. Br J Psychiatry 1993; 163(suppl 22):7-18
19. Gerlach J: New antipsychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17:298-309
20. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG: Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16:717-725
21. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE: Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992; 149:898-903
22. Medalia A, Gold JM, Merriam A: The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988; 3:249-271
23. Safferman A, Lieberman JA, Kane J, Szymanski SR, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17:247-261
24. Green AI, Schildkraut JJ: Should clozapine be a first-line treatment for schizophrenia? the rationale for a double-blind clinical trial in first-episode patients. Harvard Rev Psychiatry 1995; 3:1-9
25. Lipska BJ, Jaskiw GE, Braun AR, Weinberger DR: Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatry 1995; 38:255-262
26. Olney JW, Farber NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52:998-1007
27. Lieberman JA, Sheitman B, Kinon BJ: Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997; 17:205-229
28. Emsley RA, McCreadie RG, Livingston M, DeSmedt G, Lemmens P: Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study (abstract). J Eur Neuropsychopharmacology 1995; 5(3): 350
29. Robinson DG, Lieberman JA, Sheitman B, Alvir JM, Kane JM: Pilot study of atypical antipsychotic agents in first episode schizophrenia. Schizophr Res 1997; 24:196
30. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6:602-608
31. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NS, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
32. Moore NA, Calligaro DO, Wong DT, Bymaster FP, Tye NC: The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2:281-293
33. Moore NA, Tye NC, Axton MS, Risius FC: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992; 262:545-551
34. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, Olanzapine HGAP Study Group: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159-167
35. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAP Study Group: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:105-118
36. Beasley CM, Hamilton S, Crawford AM, Dellva MA, Tollefson G, Tran P, Blin O, Beuzen JN, Olanzapine E003 Study Group: Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125-137
37. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248-1254
38. Tran P, Dellva MA, Tollefson G, Beasley CM, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205-211
39. Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466-474
40. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
41. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
42. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
43. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
44. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
45. SAS/STAT User's Guide, version 6. 4th ed, vols 1, 2. Cary, NC. SAS Institute 1990
46. Larsen TK, McGlashan TH, Johannessen JO, Vibe-Hansen L: First episode schizophrenia, II: premorbid patterns by gender. Schizophr Bull 1996; 22:257-269
47. Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel AD, Geister S, Chakos M, Koreen A, Jody D, Kane J, Woerner M, Cooper T: Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995; 152:698-703
48. McEvoy J: Dosing issues: target symptoms and dose response. Psychiatr Annals 1995; 25:297-300
49. McCreadie RG: Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacol 1996; 6(suppl 2):S3-S5
50. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW: Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5:437-440
51. Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579-591
52. Lamberti JS, Bellnier T, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149:689-690
53. Umbricht D, Kane JM: Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22:475-483
54. Owens DG: Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994; 55(5 suppl):29-35
55. Marken PA, Haykal RF, Fisher JN: Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11:851-856